Free tool
FAERS Monitor: Abreva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020941 or its brand name (Abreva, Docosanol). Reports on generic versions are filed under their own applications.
Reports
14,600
Serious
280
2% of reports
Hospitalization
133
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective7,071
- oral herpes2,458
- condition aggravated1,967
- drug administration error1,779
- incorrect drug administration duration803
- herpes simplex706
- incorrect product administration duration642
- lip swelling560
- wrong technique in product usage process552
- product quality issue539
- inappropriate schedule of drug administration493
- application site pain448
- inappropriate schedule of product administration404
- product complaint374
- hypersensitivity319
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 1,157 |
| 2006 | 1,355 |
| 2007 | 1,648 |
| 2008 | 5 |
| 2009 | 14 |
| 2010 | 9 |
| 2011 | 17 |
| 2012 | 13 |
| 2013 | 2,116 |
| 2014 | 216 |
| 2015 | 1,337 |
| 2016 | 974 |
| 2017 | 1,006 |
| 2018 | 1,074 |
| 2019 | 855 |
| 2020 | 479 |
| 2021 | 453 |
| 2022 | 333 |
| 2023 | 852 |
| 2024 | 344 |
| 2025 | 219 |
| 2026 | 119 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,559 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| oral herpesSignal | 2,458 | 207.4 | 199.5 | 441,588 |
| herpes simplexSignal | 706 | 175.4 | 162.5 | 109,026 |
| drug administration errorSignal | 1,779 | 88.6 | 84.7 | 145,253 |
| incorrect product administration durationSignal | 642 | 44.0 | 40.7 | 26,142 |
| incorrect drug administration durationSignal | 803 | 42.3 | 39.5 | 31,462 |
| application site painSignal | 448 | 29.9 | 27.3 | 12,238 |
| lip swellingSignal | 560 | 24.6 | 22.7 | 12,475 |
| product complaintSignal | 374 | 21.6 | 19.5 | 7,216 |
| inappropriate schedule of drug administrationSignal | 493 | 10.0 | 9.2 | 3,993 |
| condition aggravatedSignal | 1,967 | 9.4 | 9.0 | 14,826 |
| drug ineffectiveSignal | 7,071 | 7.8 | 7.6 | 44,219 |
| product quality issueSignal | 539 | 5.7 | 5.3 | 2,108 |
| wrong technique in product usage processSignal | 552 | 3.9 | 3.6 | 1,212 |
| inappropriate schedule of product administrationSignal | 404 | 3.2 | 2.9 | 625 |
| hypersensitivitySignal | 319 | 2.5 | 2.2 | 282 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.